Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

9
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
9
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

578
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
578
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

625
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
625

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.

Neurology·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Early Versus Delayed Treatment with Ocrelizumab: A Multicenter, Real-World Observational Study in People with Multiple Sclerosis.

Neurology and therapy·2026
Same author

Flip angle in susceptibility-weighted imaging for the diagnosis of multiple sclerosis - Authors' reply.

The Lancet. Neurology·2026
Same author

Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Collaborative Latin American Imaging Network In Neuroimmunology Research (BRAIMS): Rationale, Structure, Challenges, and Future Directions.

Multiple sclerosis and related disorders·2026
Same journal

Patterns of psychological resilience and social avoidance among the patients of Neuromyelitis Optica Spectrum Disease: a latent profile analysis.

Multiple sclerosis and related disorders·2026
Same journal

Discontinuation of disease-modifying therapies in patients with multiple sclerosis: A retrospective case-control study.

Multiple sclerosis and related disorders·2026
Same journal

Real-world analytical and clinical evaluation of the Siemens Atellica® immunoassay for plasma neurofilament light chain in multiple sclerosis.

Multiple sclerosis and related disorders·2026
Same journal

Comparative immunopathology and clinical features of MOGAD and AQP4-IgG NMOSD in children: A scoping review.

Multiple sclerosis and related disorders·2026
Same journal

Self-perception of speech impairment in MS: Associations with dysarthria severity and speech measures.

Multiple sclerosis and related disorders·2026
Same journal

Taking progressive biology seriously in the time of B-cells and BTK.

Multiple sclerosis and related disorders·2026
See all related articles

Related Experiment Video

Updated: Apr 23, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K

Risk stratification and mitigation multiple sclerosis.

Daniel Ontaneda, Samuel Cohn, RobertJ Fox

    Multiple Sclerosis and Related Disorders
    |September 16, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Managing multiple sclerosis (MS) requires balancing treatment benefits against risks. This review outlines strategies for risk stratification and mitigation of disease-modifying agents in MS care.

    More Related Videos

    A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
    10:46

    A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

    Published on: December 9, 2015

    10.3K
    Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
    05:44

    Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

    Published on: October 13, 2023

    2.6K

    Related Experiment Videos

    Last Updated: Apr 23, 2026

    The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
    11:35

    The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

    Published on: June 30, 2014

    58.9K
    A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
    10:46

    A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

    Published on: December 9, 2015

    10.3K
    Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
    05:44

    Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

    Published on: October 13, 2023

    2.6K

    Area of Science:

    • Neurology
    • Immunology

    Background:

    • Multiple sclerosis (MS) treatment landscape is expanding with new disease-modifying agents.
    • Effective MS therapies are associated with serious potential side effects.
    • Clinicians face challenges in selecting optimal treatments based on patient-specific risk/benefit profiles.

    Purpose of the Study:

    • To review risk stratification strategies for disease-modifying agents in multiple sclerosis.
    • To present mitigation approaches for managing adverse events associated with MS therapies.
    • To support individualized treatment selection for patients with multiple sclerosis.

    Main Methods:

    • Literature review of current disease-modifying agents for multiple sclerosis.
    • Analysis of reported safety profiles and adverse events.
    • Synthesis of risk stratification and mitigation guidelines.

    Main Results:

    • Newer MS therapies offer improved efficacy but carry significant risks.
    • Understanding patient-specific factors is crucial for risk assessment.
    • Proactive risk mitigation strategies can enhance treatment safety.

    Conclusions:

    • Individualized treatment selection is paramount in managing multiple sclerosis.
    • Comprehensive risk assessment and mitigation are essential for safe and effective MS therapy.
    • This review provides a framework for clinicians to navigate the complexities of MS treatment options.